AHAM World Series - Biotechnology Fund

A feeder fund that seeks to achieve capital appreciation over medium to long term period through investments in biotechnology and biotechnology-related companies worldwide.

Fund Category
Feeder (Wholesale)

Fund Type
Growth

Target Fund Manager
Janus Henderson Investors Europe S.A.

Target Fund
Janus Henderson Horizon Fund – Biotechnology Fund

Benchmark
N/A

Base Currency
USD

Launch Date / IOP
May 30, 2024 / USD0.50(USD)
May 30, 2024 / MYR0.50(MYR Hedged)
May 30, 2024 / MYR0.50(MYR)

Financial Year End
October 31

Subscription
Cash

Initial Sales Charge
Max 5.50% of the NAV per Unit

Annual Management Fee
Max 1.80% per annum

Minimum Investment / Minimum Subsequent Investment
USD10,000 / USD5,000(USD)
MYR30,000 / MYR10,000(MYR Hedged)
MYR30,000 / MYR10,000(MYR)

As at July 31, 2025*
Fund Size / NAV Per Unit
USD0.7million / USD0.5039(USD)
MYR8.7million / MYR0.4563(MYR)
MYR13.3million / MYR0.4897(MYR Hedged)

Performance Record as at July 31 2025*



May, 2024 to July, 2025 NAV-NAV prices and assuming reinvestment of distributions into the Fund, gross investment based in USD. The value of Units may go down as well as up. Past performance is not indicative of future performance.
Source: MorningStar

Performance Table as at July 31 2025*

Total Return (%)	1 Month	1 Year	3 Year	Since Inception
Fund (USD)	6.6	-7.0	-	0.8
Fund (MYR)	8.1	-13.6	-	-8.7
Fund (MYR Hedged)	6.4	-9.5	-	-2.1

Annualised Return (%)	1 Year	3 Year	5 Year	Since Inception
Fund (USD)	-7.0	-	-	0.7
Fund (MYR)	-13.6	-	-	-8.1
Fund (MYR Hedged)	-9.5	-	-	-1.9

Calendar Year Return (%)	Year To Date	2024	2023	2022
Fund (USD)	3.3	-	-	-
Fund (MYR)	-1.4	-	-	-
Fund (MYR Hedged)	1.7	-	-	-

Source: MorningStar

Target Fund Top Holdings as at June 30 2025#

Equities	%
Vertex Pharmaceuticals	6.8
Verona Pharma	5.9
Argenx	5.7
Amgen	5.6
Soleno Therapeutics	5.4
Ascendis Pharma	4.8
Bridgebio Pharma	4.7
Akero Therapeutics	3.9
AstraZeneca	3.8
Avidity Biosciences	3.1

Asset Allocation as at July 31 2025*

Janus Henderson Horizon Fund – Biotechnology Fund Class A2 (USD)	98.4%
Cash & Cash Equivalents	1.6%

Target Fund Sector Allocation as at June 30 2025#



Income Distribution History

Distribution Policy: The fund will distribute income subject to the availability of income.
Incidentally: USD, MYR Hedged, MYR

Target Fund Country Allocation as at June 30 2025#



* The data provided above is that of the Fund and is a percentage of NAV as at July 31 2025. All figures are subject to frequent changes on a daily basis and the percentages might not add up to 100% due to rounding.

The data provided above is that of the Fund by Janus Henderson Investors Europe S.A. and is a percentage of NAV of the Target Fund as at June 30 2025 as the data is provided by Target Fund Manager after AHAM Capital publication cut-off date. Please note that asset exposure for the Target Fund is subject to frequent changes on daily basis and the percentages might not add up to 100% due to rounding.

To invest in a Class other than MYR Class and/or MYR-Hedged Class, investors are required to have a foreign currency account with any Financial Institution as all transactions relating to the particular foreign currency will ONLY be made via telegraphic transfer.

Where a distribution is declared, investors are advised that following the issue of additional Units/distribution, the NAV per Unit will be reduced from cum-distribution NAV to ex-distribution NAV.